GenAI is not the endgame in Digital Health with Lisa Suennen and Steven Wardell

You need more than GenAI. Entrepreneurs need to keep the focus on solving the buyers' biggest pain points.

GenAI is the hottest buzzword in healthcare, and it seems almost necessary to be a "GenAI Native" company in order to win VC funding today.

As founders debate whether to have a proprietary LLM and where how to have a moat in the age of GenAI, it's important not to lose sight of the most basic ingredient for an innovative product: to solve a major pain point for the buyer using whichever technology approach you use.

In this show we'll cover:

- While GenAI is all the rage, you need more than just AI

- How to know you're solving the buyer's biggest problems and how to build a moat

- Are services companies dead? Where do medical devices and disgnostics fit in?

- What to do when clinical buyers don't even want GenAI

And we'll answer your questions.

Lisa Suennen is a partner at AHA Ventures, the fund of the American Heart Association, and she's the Venture Valkyrie. Follow her at: https://www.linkedin.com/in/lisasuennen/

Steven Wardell is the Managing Partner of Wardell Advisors, a consulting firm focused on growth, fundraising, and strategic alternatives for digital health companies. He is the host of DigitalHealth InvestorTalk and the author of The Future of Digital Health. Follow for digital health insights at X.com/StevenWardell.